DRI investigators are committed to preventing and reversing type 1 diabetes.
Jay Skyler, M.D., led DPT-1, the largest multi-center Diabetes Prevention Trial in the country. Dr. Skyler and other DRI investigators remain at the forefront of diabetes prevention through their active role in the Type 1 Diabetes TrialNet.
Funded by The National Institutes of Health (NIH), this program enables researchers around the world to perform intervention studies aimed at preserving insulin-producing cells in individuals with newly-onset diabetes, or in those at risk of developing the disease.
TrialNet is also involved in studies to standardize laboratory tests to better define the disease stage and response to therapy in individuals participating in clinical trials.
Several DRI researchers are part of the national leadership of TrialNet, including:
TrialNet utilizes a nationwide infrastructure of screening sites, which is the framework for conducting new clinical trials in the U.S. and Canada.
In addition, a number of clinical centers in the United Kingdom, Italy, Germany, Finland, Australia and New Zealand have recently been included in TrialNet.
This effort established a global research network with regional clinical centers that make clinical trials accessible to families affected by type 1 diabetes.
If you would like more information about Type 1 Diabetes TrialNet and its active studies, please contact us or visit the TrialNet Web site.